{"id":1059899,"date":"2026-06-30T15:39:22","date_gmt":"2026-06-30T15:39:22","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1059899\/"},"modified":"2026-06-30T15:39:22","modified_gmt":"2026-06-30T15:39:22","slug":"first-generic-semaglutide-for-weight-loss-gets-health-canada-approval","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1059899\/","title":{"rendered":"First generic semaglutide for weight loss gets Health Canada approval"},"content":{"rendered":"<p><a style=\"display:block\" href=\"https:\/\/www.theglobeandmail.com\/resizer\/v2\/GR5ZAPEC4NGJ3A4NKLV4EFUUFI.JPG?auth=a78178d6d54612c1fb19264e439abd93c20d9b320c435db7f63d4ca145d67cab&amp;width=600&amp;height=400&amp;quality=80&amp;smart=true\" aria-haspopup=\"true\" data-photo-viewer-index=\"0\" rel=\"nofollow noopener\" target=\"_blank\">Open this photo in gallery:<\/a><\/p>\n<p class=\"figcap-text\">Boxes of Wegovy on a packaging line at Novo Nordisk&#8217;s facility in Denmark.Tom Little\/Reuters<\/p>\n<p class=\"c-article-body__text text-pr-5\">Health Canada has approved the <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/news\/2026\/06\/canada-approves-first-generic-semaglutide-for-weight-loss.html\" target=\"_blank\" rel=\"nofollow noopener\" title=\"https:\/\/www.canada.ca\/en\/health-canada\/news\/2026\/06\/canada-approves-first-generic-semaglutide-for-weight-loss.html\">first generic semaglutide injection for weight loss<\/a>.<\/p>\n<p class=\"c-article-body__text text-pr-5\">The product from the Canadian company Apotex is known as Svemia and is a generic version of the brand-name drug Wegovy from Denmark\u2019s Novo Nordisk.<\/p>\n<p class=\"c-article-body__text mv-16 l-inset text-pb-8\" data-sophi-feature=\"interstitial\"><a href=\"https:\/\/www.theglobeandmail.com\/canada\/article-generic-semaglutide-ozempic-canada-availability-price-insurance\/\" rel=\"nofollow noopener\" target=\"_blank\">Related: Generic semaglutide is now available in Canada. Where is the medication available and is it actually cheaper?<\/a><\/p>\n<p class=\"c-article-body__text text-pr-5\">Health Canada says Svemia is for the once-weekly treatment of people 12 and over, as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.<\/p>\n<p class=\"c-article-body__text text-pr-5\">It\u2019s the third generic semaglutide product approved by the department, though the <a href=\"https:\/\/www.theglobeandmail.com\/business\/economy\/article-ozempic-price-brand-name-drug-generic-semaglutide-weight-loss\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/business\/economy\/article-ozempic-price-brand-name-drug-generic-semaglutide-weight-loss\/\">first two were authorized for the treatment of Type 2 diabetes<\/a> in adults.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Generic versions of Novo Nordisk\u2019s Ozempic by India-based Dr. Reddy\u2019s Laboratories and Apotex were approved earlier this year.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Health Canada says it\u2019s reviewing six other submissions for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months.<\/p>\n","protected":false},"excerpt":{"rendered":"Open this photo in gallery: Boxes of Wegovy on a packaging line at Novo Nordisk&#8217;s facility in Denmark.Tom&hellip;\n","protected":false},"author":2,"featured_media":1059900,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[45087,9885,8047,105,4326,16,15],"class_list":["post-1059899","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-aud-growth","tag-aud-headline","tag-aud-url","tag-health","tag-medication","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116839813372907273","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1059899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1059899"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1059899\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1059900"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1059899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1059899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1059899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}